US-based biologics company LakePharma has signed an agreement with Distributed Bio to apply the latter’s SuperHuman molecular library in providing its antibody discovery service to customers in pharma and therapeutic biotech companies.
The agreement will enable LakePharma to provide better antibody discovery projects to its customers.
Also based in the US, Distributed Bio provides computational and discovery platforms for antibody discovery and engineering.
A clinical research agreement has been signed between US-based biopharmaceutical companies Array BioPharma and Bristol-Myers Squibb Company.
The former company’s investigational MEK inhibitor, binimetinib, will be investigated for potential treatment for metastatic colorectal cancer in patients with microsatellite stable tumours, when used in combination with the latter’s Opdivo (nivolumab) and Opdivo + Yervoy (ipilimumab) regimen.
Array BioPharma will sponsor the research.
Swiss-based healthcare company Galenica has raised Sfr180m ($184.54m) in gross proceeds through a private placement of 1% bonds due 2026 to institutional investors.
It has concurrently raised Sfr200m ($205.05m) through another private placement of 0.5% bonds, due June 2023.
The entire proceeds will be used to refinance the bridge loan granted at the time of its initial public offering (IPO).
Shenzen International Institute of Biological Research and Bnai Zion Medical Center have signed a memorandum of understanding (MoU), under which the former will invest in the latter for manufacturing and marketing its product in China.
Based in the US, Bnai Zion Medical Center develops cancer drugs.
The transaction is valued at $440m.